HDAC Inhibitors as Pharmacological Treatment for Duchenne Muscular Dystrophy: A Discovery Journey from Bench to Patients

Scientists describe the molecular, preclinical, and clinical evidence supporting the efficacy of histone deacetylase (HDAC) inhibitors in countering disease progression by targeting pathogenic networks of gene expression in multiple muscle-resident cell types of patients with Duchenne muscular dystrophy.